Second, the distinct roles of VASH1 and VASH2 in the tumor microenvironment suggest avenues for investigating their interactions with other angiogenic factors, such as VEGF, and immune checkpoint pathways to optimize targeted therapies and immunotherapies. This evidence concerns the gene VEGFA and neoplasm.